Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
Across the recent three months, 9 analysts have shared their insights on Fate Therapeutics (NASDAQ:FATE), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 1 | 6 | 1 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 6 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 1 | 0 |
Analysts have set 12-month price targets for Fate Therapeutics, revealing an average target of $6.11, a high estimate of $9.00, and a low estimate of $4.00. This current average has decreased by 6.0% from the previous average price target of $6.50.
Interpreting Analyst Ratings: A Closer Look
In examining recent analyst actions, we gain insights into how financial experts perceive Fate Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Edward Tenthoff | Piper Sandler | Raises | Overweight | $6.00 | $4.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Lowers | Neutral | $5.00 | $7.00 |
| Bill Maughan | Canaccord Genuity | Lowers | Buy | $9.00 | $11.00 |
| Etzer Darout | BMO Capital | Lowers | Market Perform | $6.00 | $7.00 |
| David Nierengarten | Wedbush | Lowers | Neutral | $5.00 | $7.00 |
| Edward Tenthoff | Piper Sandler | Lowers | Neutral | $4.00 | $7.00 |
| David Nierengarten | Wedbush | Maintains | Neutral | $7.00 | $7.00 |
| David Nierengarten | Wedbush | Maintains | Neutral | $7.00 | - |
| Tazeen Ahmad | B of A Securities | Raises | Underperform | $6.00 | $2.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fate Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Fate Therapeutics compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Fate Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Fate Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Fate Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Fate Therapeutics's Background
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Fate Therapeutics's Financial Performance
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Negative Revenue Trend: Examining Fate Therapeutics's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -96.74% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Fate Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2493.71% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Fate Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -12.08% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Fate Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -8.92%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.24.
Analyst Ratings: Simplified
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.